Mostrar registro simples

dc.contributor.authorViana, Marina Verçozapt_BR
dc.contributor.authorPellegrini, José Augusto Santospt_BR
dc.contributor.authorPerez, Amanda Vilaverdept_BR
dc.contributor.authorSchwarz, Patríciapt_BR
dc.contributor.authorSilva, Daiandy dapt_BR
dc.contributor.authorTeixeira, Cassianopt_BR
dc.contributor.authorGazzana, Marcelo Bassopt_BR
dc.contributor.authorRech, Tatiana Helenapt_BR
dc.date.accessioned2023-07-04T03:51:12Zpt_BR
dc.date.issued2023pt_BR
dc.identifier.issn1364-8535pt_BR
dc.identifier.urihttp://hdl.handle.net/10183/259941pt_BR
dc.description.abstractBackground: Previous studies have demonstrated a beneficial effect of early use of corticosteroids in patients with COVID-19. This study aimed to compare hospitalized patients with COVID-19 who received short-course corticosteroid treatment with those who received prolonged-course corticosteroid treatment to determine whether prolonged use of corticosteroids improves clinical outcomes, including mortality. Methods: This is a retrospective cohort study including adult patients with positive testing for Sars-CoV-2 hospitalized for more than 10 days. Data were obtained from electronic medical records. Patients were divided into two groups, according to the duration of treatment with corticosteroids: a short-course (10 days) and a prolonged-course (longer than 10 days) group. Inverse probability treatment weighting (IPTW) analysis was used to evaluate whether prolonged use of corticosteroids improved outcomes. The primary outcome was in-hospital mortality. Secondary outcomes were hospital infection and the association of different doses of corticosteroids with hospital mortality. Restricted cubic splines were used to assess the nonlinear association between mortality and dose and duration of corticosteroids use. Results: We enrolled 1,539 patients with COVID-19. Among them, 1127 received corticosteroids for more than 10 days (prolonged-course group). The in-hospital mortality was higher in patients that received prolonged course corticosteroids (39.5% vs. 26%, p < 0.001). The IPTW revealed that prolonged use of corticosteroids significantly increased mortality [relative risk (RR) = 1.52, 95% confidence interval (95% CI): 1.24-1.89]. In comparison to short course treatment, the cubic spline analysis showed an inverted U-shaped curve for mortality, with the highest risk associated with the prolonged use at 30 days (RR = 1.50, 95% CI 1.21-1.78). Conclusions: Prolonged course of treatment with corticosteroids in hospitalized patients with COVID-19 was associated with higher mortality.en
dc.format.mimetypeapplication/pdfpt_BR
dc.language.isoengpt_BR
dc.relation.ispartofCritical care : the official journal of the Critical Care Forum. London, UK. Vol. 27, no. 143 (Apr. 2023), 9 p.pt_BR
dc.rightsOpen Accessen
dc.subjectCorticosteróidespt_BR
dc.subjectCorticosteroidsen
dc.subjectCritical illnessen
dc.subjectCOVID-19pt_BR
dc.subjectInverse probability of treatment weightingen
dc.subjectSARS-CoV-2pt_BR
dc.subjectEstudos retrospectivospt_BR
dc.subjectMortalityen
dc.subjectProbabilidadept_BR
dc.subjectSARS-CoV-2en
dc.subjectUsos terapêuticospt_BR
dc.titleAssociation between prolonged corticosteroids use in COVID-19 and increased mortality in hospitalized patients : a retrospective study with inverse probability of treatment weighting analysispt_BR
dc.typeArtigo de periódicopt_BR
dc.identifier.nrb001168924pt_BR
dc.type.originEstrangeiropt_BR


Thumbnail
   

Este item está licenciado na Creative Commons License

Mostrar registro simples